Could weight loss drugs help prevent cancer? Here's what a new study found.

A new observational study indicates that GLP-1 agonists, such as Ozempic and Wegovy, may modestly reduce the risk of obesity-related cancers, particularly colorectal cancer, compared to DDP-4 inhibitors. The study of 170,030 adults with obesity and diabetes showed a 7% lower risk of developing obesity-related cancer and an 8% lower risk of death for those taking GLP-1s; women specifically experienced an 8% lower risk of obesity-related cancer and a 20% lower risk of death. While the research, funded by the NIH, suggests a potential preventative effect, further studies are needed to validate these findings, including in patients without diabetes, as the study does not establish causation.

Analysis

A new observational study involving 170,030 adults with obesity and diabetes indicates that GLP-1 agonists, such as Ozempic, Wegovy, and Zepbound, may offer a modest reduction in the risk of 14 obesity-related cancers, notably colorectal cancer, and decrease all-cause mortality compared to DDP-4 inhibitors. Specifically, patients on GLP-1s exhibited a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause. The study, funded by the National Institutes of Health and set for presentation at the 2025 American Society of Clinical Oncology conference, highlighted a more pronounced benefit for women, who saw an 8% lower risk of obesity-related cancer and a 20% lower risk of all-cause death, though the difference was not statistically significant for men. While these findings carry a "strongly positive" sentiment (0.7) and a high market impact score (0.7), with per-ticker sentiment for key GLP-1 manufacturers Novo Nordisk (NVO) and Eli Lilly (LLY) at 0.8, it is crucial to note the study does not establish causation. Further research, including longer-term studies and trials involving non-diabetic individuals, is required to validate these potential preventative effects, which, if confirmed, could significantly broaden the therapeutic scope and market for these drugs beyond diabetes and weight management, aligning with the broader understanding that over 40% of cancer fatalities are linked to modifiable lifestyle risks like excess body weight.

Key Decisions for Investors

• Investors should consider the potential for an expanded total addressable market for GLP-1 manufacturers like Novo Nordisk (NVO) and Eli Lilly (LLY), supported by the positive sentiment and market impact signals, should these cancer prevention benefits be further substantiated.
• Monitor upcoming presentations at the 2025 American Society of Clinical Oncology conference and subsequent research for validation of these findings, particularly studies establishing causality and those involving populations without diabetes, as these will be crucial for broader adoption.
• While the preliminary data is encouraging for companies in the GLP-1 space, the observational nature of this study warrants cautious optimism; definitive causal evidence will be necessary before fully pricing in a cancer prevention application.